<DOC>
	<DOCNO>NCT02985099</DOCNO>
	<brief_summary>The purpose present study evaluate effect subgingival delivery 1.2 % Rosuvastatin ( RSV ) gel adjunct scale root plan chronic periodontitis ( CP ) Type 2 diabetes mellitus patient .</brief_summary>
	<brief_title>1.2 % Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Background : The purpose double-masked , randomize , control clinical trial evaluate effect subgingival delivery 1.2 % Rosuvastatin gel adjunct scale root planing ( SRP ) clinical radiographic parameter compare method SRP plus placebo gel alone chronic periodontitis ( CP ) type 2 DM patient . Methods : Eighty CP patient type 2 DM include study . They divide two group : 1 ) SRP + 1.2 % Rosuvastatin gel ( RSV group ) ; 2 ) SRP + Placebo gel ( Placebo group ) . At baseline , 3 , 6 9 month treatment , clinical measurement , include plaque index ( PI ) , modify sulcus bleed index ( mSBI ) , probe depth ( PD ) , clinical attachment level ( CAL ) radiographic parameter intrabony defect depth ( IBD ) , percentage change radiographic defect depth reduction ( DDR % ) assess .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Type 2 diabetic patient deep pocket ( PD ≥5mm CAL ≥4mm ) vertical bone loss ≥3 mm intraoral periapical radiograph Patients ≥20 teeth history periodontal therapy precede 6 month antibiotic therapy Patients know systemic disease Patients systemic statin therapy Known suspect allergy statin supplementation Patients aggressive periodontitis Tobacco use form , smoker , alcoholic Immunocompromised patient Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>